Melphalan pharmacokinetics in children with malignant disease: Influence of body weight, renal function, carboplatin therapy and total body irradiation

British Journal of Clinical Pharmacology

Volumn 59, Issue 3, 2005, Pages 314-324

  Nath, Christa E ^a   Shaw, Peter J ^a,b   Montgomery, Kay ^a   Earl, John W ^a  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Carboplatin; Children; Melphalan pharmacokinetics; Renal function; Weight

Indexed keywords

BUSULFAN; CARBOPLATIN; ETOPOSIDE; MELPHALAN; THIOTEPA;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; BONE MARROW TRANSPLANTATION; CHILD; CHONDROSARCOMA; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; EWING SARCOMA; GLOMERULUS FILTRATION RATE; HEPATOBLASTOMA; HUMAN; HUMAN CELL; KIDNEY FUNCTION; LARGE CELL LYMPHOMA; LEUKEMIA; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MEDIASTINUM TUMOR; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RETINOBLASTOMA; RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA; WHOLE BODY RADIATION;

ADOLESCENT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; AREA UNDER CURVE; BODY WEIGHT; BONE MARROW TRANSPLANTATION; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GLOMERULAR FILTRATION RATE; HUMANS; INFANT; KIDNEY DISEASES; MELPHALAN; NEOPLASMS; TIME FACTORS; WHOLE-BODY IRRADIATION;

EID: 15244342735     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.02319.x     Document Type: Article

References (32)

1. Samuels BL, Bitran JD. High dose intravenous melphalan: a review. J Clin Oncol 1995; 13: 1786-99.
2. Shaw PJ, Pinkerton CR, Yaniv I. Melphalan combined with carboplatin dose based on glomerular filtration rate followed by autologous stem cell rescue for children with solid tumours. Bone Marrow Transplant 1996; 16: 401-5.
3. Michel G, Maraninchi D, Demeocq F, et al. Repeated courses of high dose melphalan and unpurged autologous bone marrow transplantation in children with acute non-lymphoblastic leukemia in first complete remission. Bone Marrow Transplant 1998; 3: 105-11.
4. Watanabe T, Kajiume T, Abe T, et al. Allogeneic peripheral blood stem cell transplantation in children with haematological malignancies from HLA-matched siblings. Med Paediatr Onc 2000; 34: 171-6.
5. Cornwell GG III, Pajak TF, McIntyre OR, et al. Influence of renal failure on myelosuppressive effects of melphalan: cancer and leukemia group B experience. Cancer Treat Rep 1982; 66: 475-81.
6. 2 melphalan followed by autologous stem cell transplantation in patients with advanced haematological malignancies: pharmacokinetics and toxicity. Br J Haematol 1996; 95: 527-30.
7. Sarosy G. Leyland-Jones B, Soochan P & Cheson BD. The systemic administration of intravenous melphalan. J Clin Oncol 1988; 6: 1768-82.
8. Vassal G, Tranchard B, Valteau-Couanet D, et al. Pharmacodynamics of tandem high-dose melphalan with peripheral blood stem cell transplantation in children with neuroblastoma and medulloblastoma. Bone Marrow Transplant 2001; 27: 471-7.
9. Ploin DY, Tranchard B, Guastalla JP, et al. Pharmacokinetically guided dosing for intravenous melphalan: a pilot study in patients with advanced ovarian adenocarcinoma. Eur J Cancer 1992; 28: 1311-5.
10. Reece PA, Hill HS, Green RM, et al. Renal clearance and protein binding of melphalan in patients with cancer. Cancer Chemother Pharmacol 1988; 22: 348-52.
11. Alberts DS, Chang SY, Chen HS, et al. Kinetics of intravenous melphalan. Clin Pharmacol Ther 1979; 26: 73-80.
12. Tattersall MHN, Jarman M, Newlands ES, et al. Pharmacokinetics of melphalan following oral or intravenous administration in patients with malignant disease. Eur J Cancer 1978; 14: 507-13.
13. Gera S, Musch E, Osterheld HK, Loos U. Relevance of the hydrolysis and protein binding of melphalan to the treatment of multiple myeloma. Cancer Chemother Pharmacol 1989; 23: 76-80.
14. Chang SY, Alberts DS, Farquhar D, et al. Hydrolysis and protein binding of melphalan. J Pharm Sci 1978; 67: 682-4.
15. Ardiet C, Tranchard B, Biron P, et al. Pharmacokinetics of high-dose intravenous melphalan in children and adults with forced diuresis. Cancer Chemother Pharmacol 1986; 16: 300-4.
16. Gouyette A, Hartmann O, Pico JL. Pharmacokinetics of high dose melphalan in children and adults. Cancer Chemother Pharmacol 1986; 16: 184-9.
17. Taha AK, Ahmad RA, Rogers DW, et al. Pharmacokinetics of melphalan in children following high-dose intravenous injection. Cancer Chemother Pharmacol 1983; 10: 212-6.
18. Kergueris MF, Milpied N, Moreau P, et al. Pharmacokinetics of high-dose melphalan in adults: influence of renal function. Anticancer Res 1994; 14: 2379-82.
19. Pinguet F, Martel P, Fabbro M, et al. Pharmacokinetics of high-dose intravenous melphalan in patients undergoing peripheral blood hematopoietic progenitor-cell transplantation. Anticancer Res 1997; 17: 605-12.
20. Tranchard B, Ploin DY, Minuit MP, et al. High-dose melphalan adjustment: possibility of using a test dose. Cancer Chemother Pharmacol 1989; 23: 95-100.
21. Valteau-Couanet D, Benhamou E, Vassal G, et al. Consolidation with a busulfan-containing regimen followed by stem cell transplantation in infants with poor prognosis stage 4 neuroblastoma. Bone Marrow Transplant 2000; 25: 937-42.
22. Chang SY, Alberts DS, Farquhar D, et al. High pressure liquid chromatographic analysis of melphalan in plasma. J Pharm Sci 1978; 67: 679-82.
23. Springolo V, Borella F, Finardi GP, et al. High-performance liquid chromatographic determination of m-bis (chloroethyl) aminophenyl-L-alanine in plasma. J Chromatogr 1989; 490: 224-9.
24. Villablanca J, Matthay K, Swift P, et al. Phase 1 trial of carboplatin, etoposide, melphalan and local irradiation (CEM-L1) with purged autologous bone marrow transplantation (ABMT) for high risk neuroblastoma. Med Pediatr Onc 1999; 33: 170 (Abstract O-114).
25. Ninane J, Baurain R, de Selys A, et al. High dose melphalan in children with advanced malignant disease: a pharmacokinetic study. Cancer Chemother Pharmacol 1985; 15: 263-7.
26. Tranchard B, Ardiet C, Bouffet E, et al. Effect of carboplatin on the Pharmacokinetics of melphalan administered by the intravenous route. Bull Cancer 1994; 81: 43-6.
27. Schuh A, Dandridge J, Haydon P, Littlewood TJ. Encephalopathy complicating high-dose melphalan. Bone Marrow Transplant 1999; 24: 1141-3.
28. Alberts DS, Chen H-SG, Benz D, Mason NL. Effect of renal dysfunction in dogs on the disposition and marrow toxicity of melphalan. Br J Cancer 1981; 43: 330-4.
29. Peters WP, Stuart A, Klotman M, et al. High-dose combination cyclophosphamide, cisplatin and melphalan with autologous bone marrow support. Cancer Chemother Pharmacol 1989; 23: 377-83.
30. Olver IN, Webster LK, Millward MJ, et al. A phase I and pharmacokinetics study of prolonged ambulatory-infusion carboplatin. Cancer Chemother Pharmacol 1995; 37: 79-85.
31. de Gislain C, Dumas M, d'Athis P, et al. Urinary β2-microglobulin: early indicator of high dose cisdiamminedichloroplatinum nephrotoxicity? Influence of furosemide. Cancer Chemother Pharmacol 1986; 18: 276-9.
32. Shea TC, Flaherty M, Elias A, et al. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol 1989; 7: 651-61.